 BEVERLY HILLS, Calif., May 17, 2021 PRNewswire -- GT Biopharma, Inc. GT Biopharma or the Company NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer NK cell engager TriKETM protein biologic technology platform, today reported financial results for the first quarter ended March 31, 2021 and provided a general business update. 